



**Mailing Address:**

Attn: Jen Laws  
PO Box 3009  
Slidell, LA 70459

**Chief Executive Officer:**

Jen Laws  
Phone: (313) 333-8534  
Fax: (646) 786-3825  
Email: [jen@tiicann.org](mailto:jen@tiicann.org)

**Board of Directors:**

Darnell Lewis, Chair  
Judith Montenegro, Secretary  
Dusty Garner, Treasurer

Hon. Donna Christensen, MD  
Patrick Ingram, MHSA  
Riley Johnson  
Kim Molnar  
Judith Montenegro  
Amanda Pratter

**Director Emeritus:**

William E. Arnold (*in Memoriam*)  
Jeff Coudriet (*in Memoriam*)  
Hon. Maurice Hinchey, MC (*in Memoriam*)  
Gary R. Rose, JD (*in Memoriam*)  
Kathie Heirs

**National Programs:**

340B Action Center  
PDAB Action Center

Transgender Leadership in HIV Advocacy  
HIV/HCV Co-Infection Watch

**National Groups:**

Hepatitis Education, Advocacy & Leadership  
(HEAL) Group  
Industry Advisory Group (IAG)  
National ADAP Working Group (NAWG)

September 8, 2026

Dear Members of the FDA Advisory Committee,

Community Access National Network (CANN) works to improve access to healthcare for people living with HIV/AIDS and viral hepatitis. Our work focuses on whether healthcare policies and systems give patients meaningful access to the care they need.

Many of the people we represent already devote a great deal of attention to managing their health — keeping up with treatment, working with providers, and making decisions that can carry real consequences. A cancer diagnosis can suddenly add a new set of questions and concerns to care that is already complex.

Additionally, GRAIL screening capabilities include certain cancers which either disproportionately impact people living with HIV and / or qualify as an “AIDS-defining diagnosis” when identified for a patient living with HIV, including but not limited to non-Hodgkin lymphoma and cervical cancer (AIDS-defining), colorectal & testicular cancers, anal cancer, Hodgkin lymphoma, certain head and neck cancers, lung cancer, liver / bile duct cancer, and plasma cell neoplasms. In specificity, people living with HIV are 20 to 25 times more likely to experience [anal cancer](#), 12 to 25 times more likely to develop aggressive B-cell [non-Hodgkin lymphoma](#), and 3 to 5 times more likely to be diagnosed with cervical cancer.

Early detection of these and other cancers improves the likelihood of manageable care rather than late-stage diagnoses wherein health outcomes are less certain and care far more expensive.

Whatever health conditions someone is managing, they should have a voice in the decisions about their care. That should remain true even when someone is facing a serious diagnosis, and it should be central as new approaches to cancer screening are developed and evaluated.

We believe Galleri deserves the FDA’s full consideration, and we support GRAIL’s Premarket Approval application for the multi-cancer early detection test. Thank you for considering our comments and the patient perspective they represent.

Respectfully,  
Jen Laws  
President & Chief Executive Officer  
Community Access National Network